NASDAQ$OFIX

Orthofix Medical Inc · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Orthofix reported Q3 2024 results, showing revenue increase and positive free cash flow.

Orthofix's Q3 2024 net sales increased by 7% to $196.6 million. The company reported a net loss of $(27.4) million, with Non-GAAP adjusted EBITDA of $19.2 million. Free cash flow was $5.9 million. The company reiterated its full-year 2024 financial guidance and introduced new three-year financial targets.

  • Net sales increased by 7% year-over-year to $196.6 million.
  • U.S. Spine Fixation net sales grew by 18% compared to Q3 2023.
  • Bone Growth Therapies (BGT) net sales increased by 9%.
  • Company achieved free cash flow of $5.9 million in Q3 2024.

Headline financials

Total Revenue

$197M

Previous: $184M+6.8%
EPS

-$0.71

Previous: $0.07-1114.3%
Pro Forma Adj. EBITDA %

9.2%

No prior period
Capital Expenditures

-$25.2M

Previous: -$45.7M+44.8%
Free Cash Flow

-$52.6M

Previous: -$74.6M+29.4%
Net Income

-$27.4M

Previous: -$28.9M+5.1%
Operating Income

-$18.9M

Previous: -$24.4M+22.7%
Gross Profit

$135M

Previous: $120M+12.8%
Cash & Equivalents

$30.1M

Previous: $33.7M-10.7%
Total Assets

$868M

Previous: $906M-4.2%
R&D Expense

$17.3M

Previous: $18.6M-6.8%
Stock-Based Comp

$6.53M

Previous: $6.27M+4.1%

Revenue & EPS history

Orthofix · Revenue · Quarterly

$197M

Q3 2024+6.8%vs Q3 2023
Beat estimate in 10 of 14 quarters(71%)
ActualEstimate

Revenue by segment

Orthofix · $83.1M total across 2 segments · Q3 2023

  • Bone Growth Therapies
    $53.4M+14.8%
  • Global Limb Reconstruction
    $29.7M+6.8%

Forward guidance

Orthofix reiterates its 2024 full-year guidance with net sales expected to range between $795 million to $800 million and non-GAAP adjusted EBITDA expected to range from $64 million to $69 million. The Company expects to continue to be free cash flow positive for the remainder of 2024.

Tailwinds

  • Net sales are expected to range between $795 million to $800 million, representing implied growth of 6.6% to 7.2% year-over year on a constant currency basis.
  • Non-GAAP adjusted EBITDA is expected to range from $64 million to $69 million.
  • The Company expects to continue to be free cash flow positive for the remainder of 2024.
  • Implied growth of 6.6% to 7.2% year-over-year on a constant currency basis for net sales

Headwinds

  • Guidance ranges do not contemplate any potential impact to elective procedures as a result of IV fluid shortages or other hurricane-related effects.
  • Expectations are based on the current foreign currency exchange rates and do not take into account any additional potential exchange rate changes that may occur this year.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

-0.9%

Avg return

Earnings day

-2.6%

Avg return

5 days after

-3.4%

Avg return

30 days after

48%

31 / 65 earnings

Positive

+20.3%

Q2 2014

Best reaction

-18.5%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.8%-2.8%-13.8%
Q4 2025-7.0%-0.4%-13.2%
Q3 2025-7.4%-6.8%-1.0%
Q1 2025-10.8%-10.6%-20.9%
Q4 2024-3.5%-4.2%-11.0%
Q3 2024+5.5%+4.6%+1.2%
Q2 2024+13.8%+10.8%+16.7%
Q1 2024+10.7%+8.8%+0.6%
Q4 2023+8.1%+7.1%+8.6%
Q3 2023-12.5%-20.2%-3.2%
Q2 2023+9.9%+7.6%+1.3%
Q1 2023+1.0%-2.3%+6.7%
Q4 2022-7.7%-13.2%-15.5%
Q3 2022-2.2%+4.1%+30.5%
Q2 2022-6.6%-8.8%-20.9%
Q1 2022-10.5%-14.3%-11.6%
Q4 2021+4.0%+3.5%+0.4%
Q3 2021-5.9%-10.9%-18.6%
Q2 2021+8.9%+4.1%+12.4%
Q1 2021+0.5%-2.0%-8.7%
Q4 2020+0.6%-0.5%-7.3%
Q3 2020+5.2%+13.6%+10.8%
Q2 2020+4.5%+4.6%-13.4%
Q1 2020-1.9%-6.9%+3.9%
Q4 2019-18.5%-21.5%-40.9%
Q3 2019-16.8%-17.0%-9.6%
Q2 2019+0.1%+2.6%-5.5%
Q1 2019-2.6%-0.3%-10.9%
Q4 2018-8.5%-10.0%-14.8%
Q3 2018+7.4%+8.8%+4.1%
Q2 2018-15.1%-11.9%-12.1%
Q1 2018-13.4%-14.6%-10.5%
Q4 2017+6.4%+4.6%+8.4%
Q3 2017+8.8%+5.1%+9.6%
Q2 2017+9.9%+6.8%+12.3%
Q1 2017+1.4%+3.8%+8.2%
Q4 2016-6.1%-4.8%+2.6%
Q3 2016-3.8%-6.8%-1.5%
Q2 2016-10.4%-10.5%-4.8%
Q1 2016+0.4%
Q4 2015+2.8%
Q3 2015+14.4%
Q2 2015+13.8%
Q1 2015+0.4%
Q4 2014-10.8%
Q3 2014+20.3%
Q2 2014+20.3%
Q1 2014+4.2%
Q4 2013+14.1%
Q3 2013+1.1%
Q2 2013-0.8%
Q1 2013-16.4%
Q4 2012-4.9%
Q3 2012-2.8%
Q2 2012+4.5%
Q1 2011-0.7%
Q1 2012+1.0%
Q1 2010-4.8%
Q4 2011-4.8%
Q4 2009-4.8%
Q3 2010-7.4%
Q3 2011-7.4%
Q4 2010-9.5%
Q2 2010-9.5%
Q2 2011-9.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro